FDA Grants Breakthrough Therapy Designation to Inavolisib for PIK3CA-Mutated Breast Cancer
Inavolisib was submitted to the FDA for review as a first-line treatment for advanced HR-positive, HER2-negative PIK3CA-mutated breast cancer.
Levi Garraway Mayne Pharma Group Mayne Pharma Group Limited Breakthrough Therapy Designation Patients With Breast Published December
Source: pharmacytimes.com